-
1
-
-
0029145627
-
Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines
-
Meierhoff G, Dehmel U, Gruss HJ, et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia. 1995;9(8):1368-1372.
-
(1995)
Leukemia
, vol.9
, Issue.8
, pp. 1368-1372
-
-
Meierhoff, G.1
Dehmel, U.2
Gruss, H.J.3
-
2
-
-
0030002950
-
Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells
-
Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia. 1996;10(4):588-599. (Pubitemid 26144436)
-
(1996)
Leukemia
, vol.10
, Issue.4
, pp. 588-599
-
-
Drexler, H.G.1
-
3
-
-
13344282746
-
Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias
-
Carow CE, Levenstein M, Kaufmann SH, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood. 1996;87(3):1089-1096. (Pubitemid 26043536)
-
(1996)
Blood
, vol.87
, Issue.3
, pp. 1089-1096
-
-
Carow, C.E.1
Levenstein, M.2
Kaufmann, S.H.3
Chen, J.4
Amin, S.5
Rockwell, P.6
Witte, L.7
Borowitz, M.J.8
Civin, C.I.9
Small, D.10
-
4
-
-
0026457216
-
Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages
-
Birg F, Courcoul M, Rosnet O, et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood. 1992;80(10):2584-2593.
-
(1992)
Blood
, vol.80
, Issue.10
, pp. 2584-2593
-
-
Birg, F.1
Courcoul, M.2
Rosnet, O.3
-
5
-
-
9244260192
-
Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells
-
Rosnet O, Buhring HJ, Marchetto S, et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 1996;10(2):238-248. (Pubitemid 26102887)
-
(1996)
Leukemia
, vol.10
, Issue.2
, pp. 238-248
-
-
Rosnet, O.1
Buhring, H.-J.2
Marchetto, S.3
Rappold, I.4
Lavagna, C.5
Sainty, D.6
Arnoulet, C.7
Chabannon, C.8
Kanz, L.9
Hannum, C.10
Birnbaum, D.11
-
6
-
-
0027494860
-
Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells
-
Dosil M, Wang S, Lemischka IR. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol. 1993;13(10):6572- 6585. (Pubitemid 23292651)
-
(1993)
Molecular and Cellular Biology
, vol.13
, Issue.10
, pp. 6572-6585
-
-
Dosil, M.1
Wang, S.2
Lemischka, I.R.3
-
7
-
-
9044233643
-
Expression and signal transduction of the FLT3 tyrosine kinase receptor
-
Rosnet O, Buhring HJ, deLapeyriere O, et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol. 1996;95(3-4):218-223. (Pubitemid 26000216)
-
(1996)
Acta Haematologica
, vol.95
, Issue.3-4
, pp. 218-223
-
-
Rosnet, O.1
Buhring, H.-J.2
DeLapeyriere, O.3
Beslu, N.4
Lavagna, C.5
Marchetto, S.6
Rappold, I.7
Drexler, H.G.8
Birg, F.9
Rottapel, R.10
Hannum, C.11
Dubreuil, P.12
Birnbaum, D.13
-
8
-
-
0031883328
-
FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates
-
DOI 10.1038/sj.leu.2400921
-
Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia. 1998;12(3):301-310. (Pubitemid 28138213)
-
(1998)
Leukemia
, vol.12
, Issue.3
, pp. 301-310
-
-
Lavagna-Sevenier, C.1
Marchetto, S.2
Birnbaum, D.3
Rosnet, O.4
-
9
-
-
2642705833
-
The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells
-
DOI 10.1074/jbc.273.24.14962
-
Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O. The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. J Biol Chem. 1998;273(24):14962-14967. (Pubitemid 28272788)
-
(1998)
Journal of Biological Chemistry
, vol.273
, Issue.24
, pp. 14962-14967
-
-
Lavagna-Sevenier, C.1
Marchetto, S.2
Birnbaum, D.3
Rosnet, O.4
-
10
-
-
0033020705
-
Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells
-
Zhang S, Mantel C, Broxmeyer HE. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J Leukoc Biol. 1999;65(3):372-380. (Pubitemid 29109711)
-
(1999)
Journal of Leukocyte Biology
, vol.65
, Issue.3
, pp. 372-380
-
-
Zhang, S.1
Mantel, C.2
Broxmeyer, H.E.3
-
11
-
-
0032846420
-
SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor
-
Marchetto S, Fournier E, Beslu N, et al. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia. 1999;13(9):1374-1382. (Pubitemid 29429764)
-
(1999)
Leukemia
, vol.13
, Issue.9
, pp. 1374-1382
-
-
Marchetto, S.1
Fournier, E.2
Beslu, N.3
Aurran-Schleinitz, T.4
Dubreuil, P.5
Borg, J.-P.6
Birnbaum, D.7
Rosnet, O.8
-
12
-
-
0034605042
-
Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling
-
Zhang S, Fukuda S, Lee Y, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med. 2000;192(5):719-728.
-
(2000)
J Exp Med
, vol.192
, Issue.5
, pp. 719-728
-
-
Zhang, S.1
Fukuda, S.2
Lee, Y.3
-
13
-
-
0032519768
-
c-kit ligand and flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities
-
Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood. 1998;91(4):1101-1134. (Pubitemid 28086863)
-
(1998)
Blood
, vol.91
, Issue.4
, pp. 1101-1134
-
-
Lyman, S.D.1
Jacobsen, S.E.W.2
-
14
-
-
0028318788
-
Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs
-
DOI 10.1038/368643a0
-
Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature. 1994;368(6472):643-648. (Pubitemid 24153389)
-
(1994)
Nature
, vol.368
, Issue.6472
, pp. 643-648
-
-
Hannum, C.1
Culpepper, J.2
Campbell, D.3
McClanahan, T.4
Zurawski, S.5
Bazan, J.F.6
Kastelein, R.7
Hudak, S.8
Wagner, J.9
Mattson, J.10
Luh, J.11
Duda, G.12
Martina, N.13
Peterson, D.14
Menon, S.15
Shanafelt, A.16
Muench, M.17
Kelner, G.18
Rosnet, O.19
-
15
-
-
0028203747
-
Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells
-
Lyman SD, James L, Johnson L, et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood. 1994;83(10):2795-2801.
-
(1994)
Blood
, vol.83
, Issue.10
, pp. 2795-2801
-
-
Lyman, S.D.1
James, L.2
Johnson, L.3
-
16
-
-
0027955112
-
+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells
-
Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A. 1994;91(2):459-463. (Pubitemid 24041421)
-
(1994)
Proceedings of the National Academy of Sciences of the United States of America
, vol.91
, Issue.2
, pp. 459-463
-
-
Small, D.1
Levenstein, M.2
Kim, E.3
Carow, C.4
Amin, S.5
Rockwell, P.6
Witte, L.7
Burrow, C.8
Ratajczak, M.Z.9
Gewirtz, A.M.10
Civin, C.I.11
-
17
-
-
0029097145
-
Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors
-
Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 1995;3(1):147-161.
-
(1995)
Immunity
, vol.3
, Issue.1
, pp. 147-161
-
-
Mackarehtschian, K.1
Hardin, J.D.2
Moore, K.A.3
Boast, S.4
Goff, S.P.5
Lemischka, I.R.6
-
18
-
-
0034210658
-
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells
-
McKenna HJ, Stocking KL, Miller RE, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 2000;95(11):3489-3497. (Pubitemid 30428482)
-
(2000)
Blood
, vol.95
, Issue.11
, pp. 3489-3497
-
-
McKenna, H.J.1
Stocking, K.L.2
Miller, R.E.3
Brasel, K.4
De Smedt, T.5
Maraskovsky, E.6
Maliszewski, C.R.7
Lynch, D.H.8
Smith, J.9
Pulendran, B.10
Roux, E.R.11
Teepe, M.12
Lyman, S.D.13
Peschon, J.J.14
-
19
-
-
0029957070
-
Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7
-
DOI 10.1002/eji.1830260715
-
Ray RJ, Paige CJ, Furlonger C, Lyman SD, Rottapel R. Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur J Immunol. 1996;26(7):1504-1510. (Pubitemid 26229995)
-
(1996)
European Journal of Immunology
, vol.26
, Issue.7
, pp. 1504-1510
-
-
Ray, R.J.1
Paige, C.J.2
Furlonger, C.3
Lyman, S.D.4
Rottapel, R.5
-
20
-
-
0030267526
-
The flt3 Ligand Promotes the Survival of Primitive Hemopoietic Progenitor Cells with Myeloid as Well as B Lymphoid Potential: Suppression of Apoptosis and Counteraction by TNF-alpha and TGF-beta
-
Veiby OP, Jacobsen FW, Cui L, Lyman SD, Jacobsen SE. The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. J Immunol. 1996;157(7):2953-2960. (Pubitemid 126450052)
-
(1996)
Journal of Immunology
, vol.157
, Issue.7
, pp. 2953-2960
-
-
Veiby, O.P.1
Jacobsen, F.W.2
Cui, L.3
Lyman, S.D.4
Jacobsen, S.E.W.5
-
21
-
-
0029151332
-
Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells
-
Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SD. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol. 1995;23(10):1121-1129.
-
(1995)
Exp Hematol
, vol.23
, Issue.10
, pp. 1121-1129
-
-
Broxmeyer, H.E.1
Lu, L.2
Cooper, S.3
Ruggieri, L.4
Li, Z.H.5
Lyman, S.D.6
-
22
-
-
0028952954
-
The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors
-
Hirayama F, Lyman SD, Clark SC, Ogawa M. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood. 1995;85(7):1762-1768.
-
(1995)
Blood
, vol.85
, Issue.7
, pp. 1762-1768
-
-
Hirayama, F.1
Lyman, S.D.2
Clark, S.C.3
Ogawa, M.4
-
23
-
-
0032960121
-
Flt3 ligand can promote survival and macrophage development without proliferation in myeloid progenitor cells
-
DOI 10.1016/S0301-472X(98)00072-1, PII S0301472X98000721
-
Nicholls SE, Winter S, Mottram R, Miyan JA, Whetton AD. Flt3 ligand can promote survival and macrophage development without proliferation in myeloid progenitor cells. Exp Hematol. 1999;27(4):663-672. (Pubitemid 29181442)
-
(1999)
Experimental Hematology
, vol.27
, Issue.4
, pp. 663-672
-
-
Nicholls, S.E.1
Winter, S.2
Mottram, R.3
Miyan, J.A.4
Whetton, A.D.5
-
24
-
-
0041743233
-
+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: Distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells
-
DOI 10.1182/blood-2002-06-1694
-
Sitnicka E, Buza-Vidas N, Larsson S, Nygren JM, Liuba K, Jacobsen SE. Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood. 2003;102(3):881-886. (Pubitemid 36917779)
-
(2003)
Blood
, vol.102
, Issue.3
, pp. 881-886
-
-
Sitnicka, E.1
Buza-Vidas, N.2
Larsson, S.3
Nygren, J.M.4
Liuba, K.5
Jacobsen, S.E.W.6
-
25
-
-
0030451722
-
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
-
Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911-1918. (Pubitemid 27019637)
-
(1996)
Leukemia
, vol.10
, Issue.12
, pp. 1911-1918
-
-
Nakao, M.1
Yokota, S.2
Iwai, T.3
Kaneko, H.4
Horiike, S.5
Kashima, K.6
Sonoda, Y.7
Fujimoto, T.8
Misawa, S.9
-
26
-
-
0031686409
-
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
-
Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12(9):1333-1337. (Pubitemid 28442377)
-
(1998)
Leukemia
, vol.12
, Issue.9
, pp. 1333-1337
-
-
Kiyoi, H.1
Towatari, M.2
Yokota, S.3
Hamaguchi, M.4
Ohno, R.5
Saito, H.6
Naoe, T.7
-
27
-
-
0842310394
-
The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain
-
DOI 10.1016/S1097-2765(03)00505-7
-
Griffith J, Black J, Faerman C, et al. the structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004;13(2):169-178. (Pubitemid 38183264)
-
(2004)
Molecular Cell
, vol.13
, Issue.2
, pp. 169-178
-
-
Griffith, J.1
Black, J.2
Faerman, C.3
Swenson, L.4
Wynn, M.5
Lu, F.6
Lippke, J.7
Saxena, K.8
-
28
-
-
78650073854
-
FLT3 as a therapeutic target in AML: Still challenging after all these years
-
Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116(24):5089-5102.
-
(2010)
Blood
, vol.116
, Issue.24
, pp. 5089-5102
-
-
Kindler, T.1
Lipka, D.B.2
Fischer, T.3
-
29
-
-
0141836914
-
FLT3: ITDoes matter in leukemia
-
DOI 10.1038/sj.leu.2403099
-
Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia. 2003;17(9):1738-1752. (Pubitemid 37185249)
-
(2003)
Leukemia
, vol.17
, Issue.9
, pp. 1738-1752
-
-
Levis, M.1
Small, D.2
-
30
-
-
43949093459
-
FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: A marker of transformation to acute myeloid leukemia
-
DOI 10.1016/j.cancergencyto.2008.02.006, PII S0165460808001428
-
Pinheiro RF, de Sa Moreira E, Silva MR, Alberto FL, Chauffaille Mde L. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia. Cancer Genet Cytogenet. 2008;183(2):89-93. (Pubitemid 351707708)
-
(2008)
Cancer Genetics and Cytogenetics
, vol.183
, Issue.2
, pp. 89-93
-
-
Pinheiro, R.F.1
De Sa, M.E.2
Silva, M.R.R.3
Alberto, F.L.4
Chauffaille, M.D.L.L.F.5
-
31
-
-
0035885955
-
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
-
Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752-1759.
-
(2001)
Blood
, vol.98
, Issue.6
, pp. 1752-1759
-
-
Kottaridis, P.D.1
Gale, R.E.2
Frew, M.E.3
-
32
-
-
0037114829
-
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML study group Ulm
-
DOI 10.1182/blood-2002-05-1440
-
Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372-4380. (Pubitemid 35434129)
-
(2002)
Blood
, vol.100
, Issue.13
, pp. 4372-4380
-
-
Frohling, S.1
Schlenk, R.F.2
Breitruck, J.3
Benner, A.4
Kreitmeier, S.5
Tobis, K.6
Dohner, H.7
Dohner, K.8
-
33
-
-
0036659931
-
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
-
DOI 10.1182/blood.V100.1.59
-
Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59-66. (Pubitemid 35177429)
-
(2002)
Blood
, vol.100
, Issue.1
, pp. 59-66
-
-
Schnittger, S.1
Schoch, C.2
Dugas, M.3
Kern, W.4
Staib, P.5
Wuchter, C.6
Loffler, H.7
Sauerland, C.M.8
Serve, H.9
Buchner, T.10
Haferlach, T.11
Hiddemann, W.12
-
34
-
-
0037097716
-
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis
-
DOI 10.1182/blood.V99.12.4326
-
Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326- 4335. (Pubitemid 34627197)
-
(2002)
Blood
, vol.99
, Issue.12
, pp. 4326-4335
-
-
Thiede, C.1
Steudel, C.2
Mohr, B.3
Schaich, M.4
Schakel, U.5
Platzbecker, U.6
Wermke, M.7
Bornhauser, M.8
Ritter, M.9
Neubauer, A.10
Ehninger, G.11
Illmer, T.12
-
35
-
-
77952092621
-
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
-
Ravandi F, Kantarjian H, Faderl S, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34(6):752-756.
-
(2010)
Leuk Res
, vol.34
, Issue.6
, pp. 752-756
-
-
Ravandi, F.1
Kantarjian, H.2
Faderl, S.3
-
36
-
-
79953124734
-
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
-
Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12):3294-3301.
-
(2011)
Blood
, vol.117
, Issue.12
, pp. 3294-3301
-
-
Levis, M.1
Ravandi, F.2
Wang, E.S.3
-
37
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
DOI 10.1056/NEJM200104053441402
-
Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038-1042. (Pubitemid 32267973)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.14
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
Resta, D.J.4
Reese, S.F.5
Ford, J.M.6
Capdeville, R.7
Talpaz, M.8
-
38
-
-
0035810147
-
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
-
DOI 10.1056/NEJM200104053441401
-
Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037. (Pubitemid 32267972)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.14
, pp. 1031-1037
-
-
Druker, B.J.1
Talpaz, M.2
Resta, D.J.3
Peng, B.4
Buchdunger, E.5
Ford, J.M.6
Lydon, N.B.7
Kantarjian, H.8
Capdeville, R.9
Ohno-Jones, S.10
Sawyers, C.L.11
-
39
-
-
78649931161
-
Will newer tyrosine kinase inhibitors have an impact in AML?
-
Levis MJ. Will newer tyrosine kinase inhibitors have an impact in AML? Best Pract Res Clin Haematol. 2010;23(4):489-494.
-
(2010)
Best Pract Res Clin Haematol
, vol.23
, Issue.4
, pp. 489-494
-
-
Levis, M.J.1
-
40
-
-
80052965501
-
Further activation of FLT3 mutants by FLT3 ligand
-
published ahead of print April 25, 2011 doi: 10.1038.onc.2011.110
-
Zheng R, Bailey E, Nguyen B, et al. Further activation of FLT3 mutants by FLT3 ligand [published ahead of print April 25, 2011]. Oncogene. doi: 10.1038.onc.2011.110.
-
Oncogene
-
-
Zheng, R.1
Bailey, E.2
Nguyen, B.3
-
41
-
-
79953073247
-
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
-
Sato T, Yang X, Knapper S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117(12):3286-3293.
-
(2011)
Blood
, vol.117
, Issue.12
, pp. 3286-3293
-
-
Sato, T.1
Yang, X.2
Knapper, S.3
-
42
-
-
0028803283
-
Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia
-
Lyman SD, Seaberg M, Hanna R, et al. Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood. 1995;86(11):4091-4096.
-
(1995)
Blood
, vol.86
, Issue.11
, pp. 4091-4096
-
-
Lyman, S.D.1
Seaberg, M.2
Hanna, R.3
-
43
-
-
0029856349
-
Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia
-
Wodnar-Filipowicz A, Lyman SD, Gratwohl A, Tichelli A, Speck B, Nissen C. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood. 1996;88(12):4493- 4499. (Pubitemid 26419132)
-
(1996)
Blood
, vol.88
, Issue.12
, pp. 4493-4499
-
-
Wodnar-Filipowicz, A.1
Lyman, S.D.2
Gratwohl, A.3
Tichelli, A.4
Speck, B.5
Nissen, C.6
-
44
-
-
0036943456
-
Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycoslated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy
-
DOI 10.1007/s00277-002-0535-7
-
Bojko P, Pawloski D, Stellberg W, Schroder JK, Seeber S. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy. Ann Hematol. 2002;81(9):522-528. (Pubitemid 36075505)
-
(2002)
Annals of Hematology
, vol.81
, Issue.9
, pp. 522-528
-
-
Bojko, P.1
Pawloski, D.2
Stellberg, W.3
Schroder, J.K.4
Seeber, S.5
-
45
-
-
15444350807
-
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing M(r) 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
-
Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998;4(7):1661-1672. (Pubitemid 28304727)
-
(1998)
Clinical Cancer Research
, vol.4
, Issue.7
, pp. 1661-1672
-
-
Beran, M.1
Cao, X.2
Estrov, Z.3
Jeha, S.4
Jin, G.5
O'Brien, S.6
Talpaz, M.7
Arlinghaus, R.B.8
Lydon, N.B.9
Kantarjian, H.10
-
46
-
-
77949887020
-
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
-
Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010;115(7):1425-1432.
-
(2010)
Blood
, vol.115
, Issue.7
, pp. 1425-1432
-
-
Pratz, K.W.1
Sato, T.2
Murphy, K.M.3
Stine, A.4
Rajkhowa, T.5
Levis, M.6
-
47
-
-
0033043084
-
Molecular evolution of acute myeloid leukaemia in relapse: Unstable N- ras and FLT3 genes compared with p53 gene
-
Nakano Y, Kiyoi H, Miyawaki S, et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol. 1999;104(4):659-664. (Pubitemid 29143481)
-
(1999)
British Journal of Haematology
, vol.104
, Issue.4
, pp. 659-664
-
-
Nakano, Y.1
Kiyoi, H.2
Miyawaki, S.3
Asou, N.4
Ohno, R.5
Saito, H.6
Naoe, T.7
-
48
-
-
0036785393
-
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
-
Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100(7):2393-2398.
-
(2002)
Blood
, vol.100
, Issue.7
, pp. 2393-2398
-
-
Kottaridis, P.D.1
Gale, R.E.2
Langabeer, S.E.3
Frew, M.E.4
Bowen, D.T.5
Linch, D.C.6
-
49
-
-
0036786289
-
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: A comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
-
Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100(7):2387-2392.
-
(2002)
Blood
, vol.100
, Issue.7
, pp. 2387-2392
-
-
Shih, L.Y.1
Huang, C.F.2
Wu, J.H.3
-
50
-
-
70349467775
-
Anthracycline dose intensification in acute myeloid leukemia
-
Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
-
(2009)
N Engl J Med
, vol.361
, Issue.13
, pp. 1249-1259
-
-
Fernandez, H.F.1
Sun, Z.2
Yao, X.3
-
51
-
-
28544446584
-
Acquired Isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations [13]
-
DOI 10.1038/sj.leu.2403988, PII 2403988
-
Griffiths M, Mason J, Rindl M, et al. Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations. Leukemia. 2005;19(12):2355-2358. (Pubitemid 41741640)
-
(2005)
Leukemia
, vol.19
, Issue.12
, pp. 2355-2358
-
-
Griffiths, M.1
Mason, J.2
Rindl, M.3
Akiki, S.4
McMullan, D.5
Stinton, V.6
Powell, H.7
Curtis, A.8
Bown, N.9
Craddock, C.10
-
52
-
-
12544257171
-
Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias
-
Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res. 2005;65(2):375-378.
-
(2005)
Cancer Res
, vol.65
, Issue.2
, pp. 375-378
-
-
Raghavan, M.1
Lillington, D.M.2
Skoulakis, S.3
-
53
-
-
46949095907
-
Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome
-
DOI 10.1111/j.1365-2141.2008.07196.x
-
Green C, Linch DC, Gale RE. Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome. Br J Haematol. 2008;142(3):423-426. (Pubitemid 351962174)
-
(2008)
British Journal of Haematology
, vol.142
, Issue.3
, pp. 423-426
-
-
Green, C.1
Linch, D.C.2
Gale, R.E.3
-
54
-
-
42949142189
-
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
-
DOI 10.1056/NEJMoa074306
-
Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918. (Pubitemid 351620111)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.18
, pp. 1909-1918
-
-
Schlenk, R.F.1
Dohner, K.2
Krauter, J.3
Frohling, S.4
Corbacioglu, A.5
Bullinger, L.6
Habdank, M.7
Spath, D.8
Morgan, M.9
Benner, A.10
Schlegelberger, B.11
Heil, G.12
Ganser, A.13
Dohner, H.14
-
55
-
-
80051670412
-
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: Outcomes from 133 consecutive newly-diagnosed patients from a single institution
-
published online ahead of print February 12, 2011 doi:10.1016/j.bbmt. 2011.02.003
-
Dezern AE, Sung A, Kim S, et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly-diagnosed patients from a single institution [published online ahead of print February 12, 2011]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2011.02.003.
-
Biol Blood Marrow Transplant
-
-
Dezern, A.E.1
Sung, A.2
Kim, S.3
-
56
-
-
27744451026
-
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): An analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRCAML10 and 12 trials
-
DOI 10.1182/blood-2005-03-1323
-
Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106(10):3658-3665. (Pubitemid 41609208)
-
(2005)
Blood
, vol.106
, Issue.10
, pp. 3658-3665
-
-
Gale, R.E.1
Hills, R.2
Kottaridis, P.D.3
Srirangan, S.4
Wheatley, K.5
Burnett, A.K.6
Linch, D.C.7
-
57
-
-
33847417644
-
Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML
-
letter author reply 2265
-
Bornhauser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML [letter]. Blood. 2007;109(5):2264-2265, author reply 2265.
-
(2007)
Blood
, vol.109
, Issue.5
, pp. 2264-2265
-
-
Bornhauser, M.1
Illmer, T.2
Schaich, M.3
Soucek, S.4
Ehninger, G.5
Thiede, C.6
-
58
-
-
33745626157
-
Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML
-
letter author reply 400-401
-
Meshinchi S, Arceci RJ, Sanders JE, et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML [letter]. Blood. 2006;108(1):400, author reply 400-401.
-
(2006)
Blood
, vol.108
, Issue.1
, pp. 400
-
-
Meshinchi, S.1
Arceci, R.J.2
Sanders, J.E.3
-
59
-
-
78049392920
-
How I treat acute myeloid leukemia
-
Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood. 2010;116(17):3147-3156.
-
(2010)
Blood
, vol.116
, Issue.17
, pp. 3147-3156
-
-
Rowe, J.M.1
Tallman, M.S.2
-
60
-
-
79952129510
-
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: Myths, controversies, and unknowns
-
Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood. 2011;117(8):2307-2318.
-
(2011)
Blood
, vol.117
, Issue.8
, pp. 2307-2318
-
-
Gupta, V.1
Tallman, M.S.2
Weisdorf, D.J.3
-
61
-
-
79959826306
-
Impact of allogeneic transplantation from matched related and unrelated donors on clinical outcome in younger adult AML patients with FLT3 internal tandem duplications
-
abstract Abstract 909
-
Kayser S, Dohner K, Krauter J, et al. Impact of allogeneic transplantation from matched related and unrelated donors on clinical outcome in younger adult AML patients with FLT3 internal tandem duplications [abstract]. Blood. 2010;116(21):Abstract 909.
-
(2010)
Blood
, vol.116
, Issue.21
-
-
Kayser, S.1
Dohner, K.2
Krauter, J.3
-
62
-
-
77955884680
-
Chemotherapy-phased imatinib pulses improve longterm outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00
-
Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve longterm outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28(22):3644-3652.
-
(2010)
J Clin Oncol
, vol.28
, Issue.22
, pp. 3644-3652
-
-
Bassan, R.1
Rossi, G.2
Pogliani, E.M.3
-
63
-
-
69249221392
-
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: Sustained regression before and after allogeneic stem cell transplantation
-
Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113(26):6567-6571.
-
(2009)
Blood
, vol.113
, Issue.26
, pp. 6567-6571
-
-
Metzelder, S.1
Wang, Y.2
Wollmer, E.3
-
64
-
-
79952100583
-
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation
-
Sora F, Chiusolo P, Metafuni E, et al. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. Leuk Res. 2011;35(3):422-423.
-
(2011)
Leuk Res
, vol.35
, Issue.3
, pp. 422-423
-
-
Sora, F.1
Chiusolo, P.2
Metafuni, E.3
-
65
-
-
77949877713
-
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation
-
Martin PJ, Counts GW, Jr., Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28(6):1011-1016.
-
(2010)
J Clin Oncol
, vol.28
, Issue.6
, pp. 1011-1016
-
-
Martin, P.J.1
Counts Jr., G.W.2
Appelbaum, F.R.3
-
66
-
-
78649967669
-
Lestaurtinib FLT3 inhibitory activity is modulated by concomitant azole therapy and may influence relapse risk
-
abstract Abstract 326
-
Knapper S, Burnett A, Hills RK, Small D, Levis M. Lestaurtinib FLT3 inhibitory activity is modulated by concomitant azole therapy and may influence relapse risk [abstract]. Blood. 2009;114(22):Abstract 326.
-
(2009)
Blood
, vol.114
, Issue.22
-
-
Knapper, S.1
Burnett, A.2
Hills, R.K.3
Small, D.4
Levis, M.5
-
67
-
-
77950423964
-
A phase 1B study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: Overall survival of patients whose blasts have FLT3 mutations is similar to those with wild type FLT3
-
abstract Abstract 634
-
Stone R, Fischer JT, Paquette R, et al. A phase 1B study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have FLT3 mutations is similar to those with wild type FLT3 [abstract]. Blood. 2009;114:Abstract 634.
-
(2009)
Blood
, vol.114
-
-
Stone, R.1
Fischer, J.T.2
Paquette, R.3
-
68
-
-
79952086942
-
Therapeutic advances in acute myeloid leukemia
-
Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494.
-
(2011)
J Clin Oncol
, vol.29
, Issue.5
, pp. 487-494
-
-
Burnett, A.1
Wetzler, M.2
Lowenberg, B.3
-
69
-
-
59749098583
-
Breast cancer after use of estrogen plus progestin in postmenopausal women
-
Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360(6):573-587.
-
(2009)
N Engl J Med
, vol.360
, Issue.6
, pp. 573-587
-
-
Chlebowski, R.T.1
Kuller, L.H.2
Prentice, R.L.3
-
70
-
-
33750983605
-
Correction of anemia with epoetin alfa in chronic kidney disease
-
DOI 10.1056/NEJMoa065485
-
Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098. (Pubitemid 44749317)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.20
, pp. 2085-2098
-
-
Singh, A.K.1
Szczech, L.2
Tang, K.L.3
Barnhart, H.4
Sapp, S.5
Wolfson, M.6
Reddan, D.7
-
71
-
-
45149131667
-
Effects of intensive glucose lowering in type 2 diabetes
-
DOI 10.1056/NEJMoa0802743
-
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. (Pubitemid 351831356)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.24
, pp. 2545-2559
-
-
Friedewald, W.T.1
Buse, J.B.2
Bigger, J.T.3
Byington, R.P.4
Cushman, W.C.5
Gerstein, H.C.6
Ginsberg, H.N.7
Goff Jr., D.C.8
Grimm Jr., R.H.9
Ismail-Beigi, F.10
Probstfield, J.L.11
Simons-Morton, D.G.12
|